

Actinium Pharmaceuticals, Inc.  
Form 8-K  
March 09, 2018

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): March 6, 2018

**ACTINIUM PHARMACEUTICALS, INC.**

(Exact name of registrant as specified in its charter)

<b>Delaware</b>	<b>000-52446</b>	<b>74-2963609</b>
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

<b>275 Madison Avenue, 7th Floor</b>	<b>10016</b>
<b>New York, NY</b>	
(Address of principal executive offices)	(Zip Code)

Registrant's telephone number, including area code: **(646) 677-3870**

**N/A**  
(Former name or former address, if changed since last report)

Edgar Filing: Actinium Pharmaceuticals, Inc. - Form 8-K

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a -12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

**Item 8.01 Other Events.**

On March 6 and March 9, 2018, Actinium Pharmaceuticals, Inc. (“Actinium”) completed its previously announced rights offering pursuant to its effective registration statement on Form S-3, as amended (Registration Statement No. 333-216748), previously filed with and declared effective by the Securities and Exchange Commission (the “SEC”), and a prospectus and prospectus supplements filed with the SEC (the “Rights Offering”). Pursuant to the Rights Offering, Actinium sold an aggregate of 30,125,326 units consisting of an aggregate of 30,125,326 shares of common stock, 7,531,304 series A warrants and 22,593,967 series B warrants, with each series A warrant exercisable for one share of Common Stock at an exercise price of \$0.60 per share and each series B warrant exercisable for one share of Common Stock at an exercise price of \$0.70 per share, resulting in gross proceeds to Actinium of approximately \$15.1 million, and net proceeds of approximately \$13.9 million after deducting expenses relating to dealer-manager fees and expenses, and excluding any proceeds received upon exercise of any warrants.

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**ACTINIUM**

Dated: March 9, 2018 **PHARMACEUTICALS,  
INC.**

By: */s/ Sandesh Seth*

Name: Sandesh Seth

Title: CEO & Chairman